^
Association details:
| Biomarker: | MCL1 amplification |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | fadraciclib (CYC065) (CDK9 inhibitor, CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Phase 1 safety, pharmacokinetic and pharmacodynamic study of fadraciclib (CYC065), a cyclin dependent kinase inhibitor, in patients with advanced cancers
Published date:
10/26/2020
Excerpt:
Cyclacel Pharmaceuticals...announced clinical data demonstrating safety, anti-tumor activity and good oral bioavailability of Cyclacel's CDK2/9 inhibitor fadraciclib...A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib.
Trial ID:
